Company / Capital Expenditures
Cytek Biosciences, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$4.1M
FY2025
5-year range
$1.5M / $9.7M
FY2021-FY2025
Trend
+15.9%
vs FY2024
Sector context
#132 of 151
Health Care
What the data says
Cytek Biosciences, Inc.'s capital expenditures of $4M is lower than 87% of companies in the Health Care sector (FY2025). Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $4M.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +21.4%.
Declined from $5M to $4M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -25.2%
- 5-Year CAGR
- +21.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 151This company $4.1M Sector average $271.7M
▼
-98.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.4%, indicating consistent growth.
- In FY2025, capital expenditures increased 15.9% year-over-year.
- Ranks #132 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.1M | +15.9% |
| FY2024 | $3.5M | -24.2% |
| FY2023 | $4.6M | -52.3% |
| FY2022 | $9.7M | +530.1% |
| FY2021 | $1.5M | +0.0% |
| FY2020 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026